Key points: - Founded November 2015
- Melbourne-based with team in Europe, US and Japan
- Located in the Parkville biotech precinct
- IPO, listed on the ASX in November 2017
- Raised a total of AUD $58.5m (Seed + IPO)
- Fully funded for 24 months
- Mission: to become a leading oncology company in the
- field of “molecularly-targeted radiation” (MTR)
- Two major disease focus areas:
- Neuro-oncology (glioblastoma)
- Urology (renal / prostate)
For more, watch co-founder and CEO Dr Christian Behrenbruch present.
